바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 유형별(안전성, 유효성), 용도별(진단, 맞춤형 의료), 질환별(신경질환, 암), 지역별, 부문별 예측(2023-2030년)

Biomarkers Market Growth & Trends:

The global biomarkers market size is expected to reach USD 181.03 billion by 2030, registering a CAGR of 13.3% over the forecast period, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck's immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company's recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights:

• The safety segment held the largest share in 2022 owing to the increased adoption of safety biomarkers in drug discovery and development

• The efficacy segment will register the fastest growth rate from 2023 to 2030 due to a rise in strategic collaborations for promoting research activities

• The drug discovery & development segment accounted for the largest share in 2022 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery

• The cancer disease segment dominated the industry in 2022. However, the neurological diseases segment is anticipated to record the fastest CAGRover the forecast years

• Asia Pacific is expected to be the fastest-growing region over the forecast period due to the rising investments by key players and increasing disease prevalence in the region

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment scope
  • 1.1.2 Regional scope
  • 1.1.3 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database:
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Competitive Insights

Chapter 3 Biomarkers Market Variables, Trends, & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market
• 3.2 Market Dynamics
  • 3.2.1 Market drivers analysis
    • 3.2.1.1 Increasing funding for biomarkers
    • 3.2.1.2 Increasing prevalence of chronic diseases
    • 3.2.1.3 Technological advancements
  • 3.2.2 Market restraint analysis
    • 3.2.2.1 Lack of reimbursement policies for biomarkers treatment
• 3.3 Penetration & Growth Prospect Mapping
• 3.4 Influenza Vaccine: Market Analysis Tools
  • 3.4.1 Industry analysis - Porter's
  • 3.4.2 PESTLE analysis
• 3.5 Regulatory Framework
• 3.6 Pricing Analysis

Chapter 4 Biomarkers Market Segment Analysis, By Type, 2018-2030 (USD Billion)

• 4.1 Definition and Scope
• 4.2 Type Market Share Analysis, 2022 & 2030
• 4.3 Segment Dashboard
• 4.4 Global Biomarkers Market, by Type, 2018 to 2030
• 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 4.5.1 Safety
    • 4.5.1.1 Safety biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 4.5.2 Efficacy
    • 4.5.2.1 Efficacy biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 4.5.3 Validation
    • 4.5.3.1 Validation biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Biomarkers Market Segment Analysis, By Application 2018-2030 (USD Billion)

• 5.1 Definition and Scope
• 5.2 Application Market Share Analysis, 2022 & 2030
• 5.3 Segment Dashboard
• 5.4 Global Biomarkers Market, by Application, 2018 to 2030
• 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.5.1 Diagnostics
    • 5.5.1.1 Diagnostics market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 5.5.2 Drug Discovery & Development
    • 5.5.2.1 Drug discovery & development market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 5.5.3 Personalized Medicine
    • 5.5.3.1 Personalized medicine market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 5.5.4 Others
    • 5.5.4.1 Other applications market estimates & forecasts, 2018 - 2030 (USD Billion)

Chapter 6 Biomarkers Market Segment Analysis, By Disease, 2018-2030 (USD Billion)

• 6.1 Definition and Scope
• 6.2 Disease Market Share Analysis, 2022 & 2030
• 6.3 Segment Dashboard
• 6.4 Global Biomarkers Market, by Disease, 2018 to 2030
• 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.5.1 Cancer
    • 6.5.1.1 Cancer biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 6.5.2 Cardiovascular Diseases
    • 6.5.2.1 Cardiovascular disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 6.5.3 Neurological Diseases
    • 6.5.3.1 Neurological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 6.5.4 Immunological Diseases
    • 6.5.4.1 Immunological disease biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)
  • 6.5.5 Others
    • 6.5.5.1 Other diseases biomarkers market estimates & forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Biomarkers Market Segment Analysis, By Region, 2018 - 2030 (USD Billion)

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2022 & 2030
• 7.3 Regional Market Dashboard
• 7.4 Regional Market Snapshot
• 7.5 SWOT Analysis
  • 7.5.1 North America
  • 7.5.2 Europe
  • 7.5.3 Asia Pacific
  • 7.5.4 Latin America
  • 7.5.5 Middle East and Africa
• 7.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
  • 7.6.1 North America
    • 7.6.1.1 North America biomarkers market , 2018 - 2030 (USD Billion)
    • 7.6.1.2 U.S.
    • 7.6.1.2.1 Key Country Dynamics
    • 7.6.1.2.2 Competitive Scenario
    • 7.6.1.2.3 Regulatory Framework
    • 7.6.1.2.4 Reimbursement Scenario
    • 7.6.1.2.5 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.1.3 Canada
    • 7.6.1.3.1 Key Country Dynamics
    • 7.6.1.3.2 Competitive Scenario
    • 7.6.1.3.3 Regulatory Framework
    • 7.6.1.3.4 Reimbursement Scenario
    • 7.6.1.3.5 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6.2 Europe
    • 7.6.2.1 Europe biomarkers market, 2018 - 2030 (USD Billion)
    • 7.6.2.2 U.K.
    • 7.6.2.2.1 Key Country Dynamics
    • 7.6.2.2.2 Competitive Scenario
    • 7.6.2.2.3 Regulatory Framework
    • 7.6.2.2.4 Reimbursement Scenario
    • 7.6.2.2.5 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.3 Germany
    • 7.6.2.3.1 Key Country Dynamics
    • 7.6.2.3.2 Competitive Scenario
    • 7.6.2.3.3 Regulatory Framework
    • 7.6.2.23.4 Reimbursement Scenario
    • 7.6.2.3.5 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.4 Spain
    • 7.6.2.4.1 Key Country Dynamics
    • 7.6.2.4.2 Competitive Scenario
    • 7.6.2.4.3 Regulatory Framework
    • 7.6.2.4.4 Reimbursement Scenario
    • 7.6.2.4.5 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.5 France
    • 7.6.2.5.1 Key Country Dynamics
    • 7.6.2.5.2 Competitive Scenario
    • 7.6.2.5.3 Regulatory Framework
    • 7.6.2.5.4 Reimbursement Scenario
    • 7.6.2.5.5 France market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.6 Italy
    • 7.6.2.6.1 Key Country Dynamics
    • 7.6.2.6.2 Competitive Scenario
    • 7.6.2.6.3 Regulatory Framework
    • 7.6.2.6.4 Reimbursement Scenario
    • 7.6.2.6.5 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.7 Denmark
    • 7.6.2.7.1 Key Country Dynamics
    • 7.6.2.7.2 Competitive Scenario
    • 7.6.2.7.3 Regulatory Framework
    • 7.6.2.7.4 Reimbursement Scenario
    • 7.6.2.7.5 Denmark market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.8 Sweden
    • 7.6.2.8.1 Key Country Dynamics
    • 7.6.2.8.2 Competitive Scenario
    • 7.6.2.8.3 Regulatory Framework
    • 7.6.2.8.4 Reimbursement Scenario
    • 7.6.2.8.5 Sweden market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2.9 Norway
    • 7.6.2.9.1 Key Country Dynamics
    • 7.6.2.9.2 Competitive Scenario
    • 7.6.2.9.3 Regulatory Framework
    • 7.6.2.9.4 Reimbursement Scenario
    • 7.6.2.9.5 Norway market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6.3 Asia Pacific
    • 7.6.3.1 Asia Pacific biomarkers market, 2018 - 2030 (USD Billion)
    • 7.6.3.2 Japan
    • 7.6.3.2.1 Key Country Dynamics
    • 7.6.3.2.2 Competitive Scenario
    • 7.6.3.2.3 Regulatory Framework
    • 7.6.3.2.4 Reimbursement Scenario
    • 7.6.3.2.5 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3.3 China
    • 7.6.3.3.1 Key Country Dynamics
    • 7.6.3.3.2 Competitive Scenario
    • 7.6.3.3.3 Regulatory Framework
    • 7.6.3.3.4 Reimbursement Scenario
    • 7.6.3.3.5 China market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3.4 India
    • 7.6.3.4.1 Key Country Dynamics
    • 7.6.3.4.2 Competitive Scenario
    • 7.6.3.4.3 Regulatory Framework
    • 7.6.3.4.4 Reimbursement Scenario
    • 7.6.3.4.5 India market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3.5 South Korea
    • 7.6.3.5.1 Key Country Dynamics
    • 7.6.3.5.2 Competitive Scenario
    • 7.6.3.5.3 Regulatory Framework
    • 7.6.3.5.4 Reimbursement Scenario
    • 7.6.3.25.5 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3.6 Australia
    • 7.6.3.6.1 Key Country Dynamics
    • 7.6.3.6.2 Competitive Scenario
    • 7.6.3.6.3 Regulatory Framework
    • 7.6.3.6.4 Reimbursement Scenario
    • 7.6.3.6.5 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3.7 Thailand
    • 7.6.3.7.1 Key Country Dynamics
    • 7.6.3.7.2 Competitive Scenario
    • 7.6.3.7.3 Regulatory Framework
    • 7.6.3.7.4 Reimbursement Scenario
    • 7.6.3.7.5 Thailand market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6.4 Latin America
    • 7.6.4.1 Latin America biomarkers market, 2018 - 2030 (USD Billion)
    • 7.6.4.2 Brazil
    • 7.6.4.2.1 Key Country Dynamics
    • 7.6.4.2.2 Competitive Scenario
    • 7.6.4.2.3 Regulatory Framework
    • 7.6.4.2.4 Reimbursement Scenario
    • 7.6.4.2.5 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.4.3 Mexico
    • 7.6.4.3.1 Key Country Dynamics
    • 7.6.4.3.2 Competitive Scenario
    • 7.6.4.3.3 Regulatory Framework
    • 7.6.4.3.4 Reimbursement Scenario
    • 7.6.4.3.5 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.4.4 Argentina
    • 7.6.4.4.1 Key Country Dynamics
    • 7.6.4.4.2 Competitive Scenario
    • 7.6.4.4.3 Regulatory Framework
    • 7.6.4.4.4 Reimbursement Scenario
    • 7.6.4.4.5 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6.5 MEA
    • 7.6.5.1 MEA biomarkers market, 2018 - 2030 (USD Billion)
    • 7.6.5.2 South Africa
    • 7.6.5.2.1 Key Country Dynamics
    • 7.6.5.2.2 Competitive Scenario
    • 7.6.5.2.3 Regulatory Framework
    • 7.6.5.2.4 Reimbursement Scenario
    • 7.6.5.2.5 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.5.3 Saudi Arabia
    • 7.6.5.3.1 Key Country Dynamics
    • 7.6.5.3.2 Competitive Scenario
    • 7.6.5.3.3 Regulatory Framework
    • 7.6.5.3.4 Reimbursement Scenario
    • 7.6.5.3.5 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.5.4 UAE
    • 7.6.5.4.1 Key Country Dynamics
    • 7.6.5.4.2 Competitive Scenario
    • 7.6.5.4.3 Regulatory Framework
    • 7.6.5.4.4 Reimbursement Scenario
    • 7.6.5.4.5 UAE market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.5.5 Kuwait
    • 7.6.5.5.1 Key Country Dynamics
    • 7.6.5.5.2 Competitive Scenario
    • 7.6.5.5.3 Regulatory Framework
    • 7.6.5.5.4 Reimbursement Scenario
    • 7.6.5.5.5 Kuwait market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 8 Biomarkers Market - Competitive Analysis

• 8.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.1.1 Ansoff matrix
  • 8.1.2 Heat map analysis
  • 8.1.3 Major Deals and Strategic Alliances Analysis
    • 8.1.3.1 Joint Ventures
    • 8.1.3.2 Licensing Agreements
    • 8.1.3.3 Product Launches
    • 8.1.3.1 Conferences and Campaigns
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market Leaders
• 8.3 Vendor Landscape
  • 8.3.1 List of key distributors and channel partners
  • 8.3.2 Key customers
• 8.4 Public Companies
  • 8.4.1 Competitive Dashboard Analysis
    • 8.4.1.1 Market Differentiators
• 8.5 Private Companies
  • 8.5.1 List of key emerging companies
• 8.6 Company Profiles
  • 8.6.1 F. Hoffmann-La Roche Ltd
    • 8.6.1.1 Company overview
    • 8.6.1.2 Financial performance
    • 8.6.1.3 Product benchmarking
    • 8.6.1.4 Strategic Initiatives
  • 8.6.2 Abbott
    • 8.6.2.1 Company overview
    • 8.6.2.2 Financial performance
    • 8.6.2.3 Product benchmarking
    • 8.6.2.4 Strategic Initiatives
  • 8.6.3 Epigenomics AG
    • 8.6.3.1 Company overview
    • 8.6.3.2 Financial performance
    • 8.6.3.3 Product benchmarking
    • 8.6.3.4 Strategic Initiatives
  • 8.6.4 General Electric
    • 8.6.4.1 Company overview
    • 8.6.4.2 Financial performance
    • 8.6.4.3 Product benchmarking
    • 8.6.4.4 Strategic Initiatives
  • 8.6.5 Johnson & Johnson Services, Inc.
    • 8.6.5.1 Company overview
    • 8.6.5.2 Financial performance
    • 8.6.5.3 Product benchmarking
    • 8.6.5.4 Strategic Initiatives
  • 8.6.6 Thermo Fisher Scientific Inc.
    • 8.6.6.1 Company overview
    • 8.6.6.2 Financial performance
    • 8.6.6.3 Product benchmarking
    • 8.6.6.4 Strategic Initiatives
  • 8.6.7 Bio-Rad Laboratories, Inc.
    • 8.6.7.1 Company overview
    • 8.6.7.2 Financial performance
    • 8.6.7.3 Product benchmarking
    • 8.6.7.4 Strategic initiatives
  • 8.6.8 Siemens Healthcare GmbH
    • 8.6.8.1 Company overview
    • 8.6.8.2 Financial performance
    • 8.6.8.3 Product benchmarking
    • 8.6.8.4 Strategic initiatives
  • 8.6.9 QIAGEN
    • 8.6.9.1 Company overview
    • 8.6.9.2 Financial performance
    • 8.6.9.3 Product benchmarking
    • 8.6.9.4 Strategic initiatives